Epizyme Inc. (EPZM)

13.05
0.63 5.07
NASDAQ : Health Technology
Prev Close 12.42
Open 12.50
Day Low/High 12.45 / 13.10
52 Wk Low/High 5.14 / 16.10
Volume 730.87K
Avg Volume 766.80K
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 1.06B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Epizyme Announces Clinical Data From Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) To Be Presented At EORTC-NCI-AACR Symposium

Epizyme Announces Clinical Data From Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) To Be Presented At EORTC-NCI-AACR Symposium

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its ...

Epizyme, Inc. To Present At Upcoming Events In October

Epizyme, Inc. To Present At Upcoming Events In October

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three ...

Epizyme (EPZM) Downgraded From Hold to Sell

Epizyme (EPZM) Downgraded From Hold to Sell

Epizyme (EPZM) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.

Ratings Changes Today

Upgrades: BBOX, CBF, ITI, LPL, NBHC, OBAS, PLCE Downgrades: BORN, EPZM, GSB Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Epizyme Appoints Peter Ho, M.D., Ph.D., As Chief Development Officer And Michael Shih, J.D., As Vice President, Business Development

Epizyme Appoints Peter Ho, M.D., Ph.D., As Chief Development Officer And Michael Shih, J.D., As Vice President, Business Development

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the appointments of Peter Ho,...

Epizyme Announces Resignation Of President And Chief Financial Officer Jason Rhodes

Epizyme Announces Resignation Of President And Chief Financial Officer Jason Rhodes

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Jason Rhodes, President and...

Epizyme To Present At Upcoming Conferences In September

Epizyme To Present At Upcoming Conferences In September

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in five ...

Epizyme First Look at Blood Cancer Drug Encourages

Epizyme First Look at Blood Cancer Drug Encourages

Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.

Today's Perilous Reversal Stock: Epizyme (EPZM)

Today's Perilous Reversal Stock: Epizyme (EPZM)

Trade-Ideas LLC identified Epizyme (EPZM) as a "perilous reversal" (up big yesterday but down big today) candidate

Epizyme Announces Second Quarter 2014 Financial Results And Provides Corporate Update

Epizyme Announces Second Quarter 2014 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced second quarter 2014 ...

Epizyme Presents Pre-Clinical Data And Early Clinical Observations From Ongoing Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) At ASH Meeting On Lymphoma Biology

Epizyme Presents Pre-Clinical Data And Early Clinical Observations From Ongoing Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) At ASH Meeting On Lymphoma Biology

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early ...

Epizyme, Inc. To Report Second Quarter Financial Results And Provide Corporate Update On August 13, 2014

Epizyme, Inc. To Report Second Quarter Financial Results And Provide Corporate Update On August 13, 2014

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a ...

Yellen's Finger-Pointing Folly

If you don't like speculation, just hike the margin requirement.

Ratings Changes Today

Upgrades: EPZM, FIG Downgrades: BBW, TTEK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

Upgrades: FFBC, GRT, GTS, QEP, RDY Downgrades: None Initiations: EPZM, FRBA, KMDA Read on to get TheStreet Quant Ratings' detailed report:

Dueling Gurus; Impact of Lower Interest Rates: Jim Cramer's Best Blogs

Dueling Gurus; Impact of Lower Interest Rates: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the past week about what lies ahead for stocks and the dilemma presented by lower interest rates.

Dueling Gurus

Tepper is cautious, and Birinyi is bullish, so let's have a look.

5 Hated Earnings Stocks You Should Love

5 Hated Earnings Stocks You Should Love

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

'Mad Money' Lightning Round: Stick With Baidu

'Mad Money' Lightning Round: Stick With Baidu

Cramer thinks Genomic Health can go lower, doesn't like Molycorp but likes SandRidge Energy and its CEO.

Epizyme is Now Oversold (EPZM)

Epizyme is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Top Insider Trades: EPZM IDTI GAIN GNCA

Top Insider Trades: EPZM IDTI GAIN GNCA

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

3 Biotech Stocks Rising on Big Volume

3 Biotech Stocks Rising on Big Volume

Keep these biotech stocks trading on unusual volume on your radar.

J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

Biotechnology stocks have been front and center this week amidst the J.P. Morgan Healthcare conference, the big conference held in San Francisco each January where so many companies reveal important outlooks for the year and important pipeline updates. Historically, biotechnology stocks have outperformed during this conference week -- and we have seen broad-based strength from the group -- but more importantly, investors are provided with a reiteration of some of the strong themes that will dominate 2014...

3 Stocks Rising on Unusual Volume

3 Stocks Rising on Unusual Volume

Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

'Mad Money' Lightning Round: Don't Sell Lumber Liquidators Yet

'Mad Money' Lightning Round: Don't Sell Lumber Liquidators Yet

Cramer doesn't like Gigamon or Compass Minerals and really dislikes Epizyme.

Jim Cramer's 'Mad Money' Recap: A Confused Market

Jim Cramer's 'Mad Money' Recap: A Confused Market

Is good news for the economy bad news for stocks? That's the question that's been plaguing the markets for the past three years, Cramer says.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

A Time to Test Biotechs' Strength

A Time to Test Biotechs' Strength

The fundamentals are good and most of the companies are sound, but a string of soaring IPOs has some investors asking whether the run can last.

'Mad Money' Lightning Round: Buy, Buy, Buy Vodafone

'Mad Money' Lightning Round: Buy, Buy, Buy Vodafone

Cramer says be careful on Micron Technology but buy Kroger, which can go to $245.

TheStreet Quant Rating: D (Sell)